Medicare Enrolled
Dr. Sessine Najjar, M.D.
Infectious Disease · Clifton, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Najjar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Najjar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Najjar
Dr. Sessine Najjar is an infectious disease specialist in Clifton, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Najjar performed 7,027 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Najjar received a total of $12,557 from 48 pharmaceutical and/or device companies across 887 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Najjar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 6% volume in NJ
$12,557 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗7,027
Medicare services
Top 6% in NJ for infectious disease
Not available
Unique patients (not deduplicated)
$25
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, meropenem, 100 mg | 2,971 | $0 | $1 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
1,268 | $0 | $2 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
994 | $57 | $91 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
443 | $105 | $176 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
406 | $74 | $126 |
| Vancomycin injection, 500 mg A 500 mg dose of vancomycin antibiotic is administered via injection. |
317 | $2 | $5 |
| Ertapenem sodium injection, 500 mg An injection of ertapenem sodium, an antibiotic medication, administered at a dose of 500 mg. |
214 | $10 | $30 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
78 | $71 | $72 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
78 | $34 | $35 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
66 | $10 | $26 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
58 | $142 | $153 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
31 | $139 | $202 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
28 | $283 | $310 |
| COVID-19 amplified DNA/RNA probe detection A laboratory test that uses amplified DNA or RNA probes to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) antigen. |
26 | $50 | $65 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
26 | $34 | $35 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
23 | $138 | $228 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
14.1% high complexity
67.9% medium
18.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,557
Total received (2018-2024)
Avg $1,794/year across 7 years
Top 11% in NJ for infectious disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
48
Companies
887
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,630
2023
$1,636
2022
$1,707
2021
$1,893
2020
$1,786
2019
$2,191
2018
$1,712
Payments by company (2024)
Gilead Sciences, Inc.
$472
ViiV Healthcare Company
$246
Merck Sharp & Dohme LLC
$197
Novo Nordisk Inc
$94
Insmed, Inc.
$82
Cumberland Pharmaceuticals, Inc.
$81
GlaxoSmithKline, LLC.
$63
PFIZER INC.
$59
Amgen Inc.
$55
EMD Serono, Inc.
$46
ABBVIE INC.
$42
Shionogi Inc
$35
Lilly USA, LLC
$32
Phathom Pharmaceuticals, Inc.
$31
Grifols USA, LLC
$22
Janssen Pharmaceuticals, Inc
$17
Napo Pharmaceuticals Inc
$15
Mannkind Corporation
$14
AstraZeneca Pharmaceuticals LP
$14
AIMMUNE THERAPEUTICS, INC.
$14
Top 3 companies account for 56.1% of 2024 payments
All-time payments by company (2018-2024) ›
Gilead Sciences, Inc.
$2,571
ViiV Healthcare Company
$1,987
Novo Nordisk Inc
$1,202
Janssen Biotech, Inc.
$1,184
Insmed, Inc.
$470
Lilly USA, LLC
$468
Merck Sharp & Dohme Corporation
$459
Merck Sharp & Dohme LLC
$456
SANOFI-AVENTIS U.S. LLC
$402
Theratechnologies Inc.
$343
GlaxoSmithKline, LLC.
$326
PFIZER INC.
$274
EMD Serono, Inc.
$272
Amgen Inc.
$196
ABBVIE INC.
$192
AstraZeneca Pharmaceuticals LP
$174
Cumberland Pharmaceuticals, Inc.
$166
Janssen Products, LP
$161
Paratek Pharmaceuticals, Inc.
$125
Boehringer Ingelheim Pharmaceuticals, Inc.
$115
Mannkind Corporation
$103
La Jolla Pharmaceutical Company
$90
ARBOR PHARMACEUTICALS, INC.
$89
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$60
Kowa Pharmaceuticals America, Inc.
$59
Theravance Biopharma, Inc.
$57
Melinta Therapeutics, Inc.
$53
Exact Sciences Corporation
$45
MannKind Corporation
$43
AbbVie Inc.
$41
Napo Pharmaceuticals Inc
$36
Shionogi Inc
$35
Phathom Pharmaceuticals, Inc.
$31
Octapharma USA, Inc.
$29
Melinta Therapeutics, LLC
$28
TETRAPHASE PHARMACEUTICALS, INC.
$28
Allergan, Inc.
$27
Grifols USA, LLC
$22
Janssen Pharmaceuticals, Inc
$17
Pharming Healthcare, Inc.
$15
Sanofi Pasteur Inc.
$14
Azurity Pharmaceuticals, Inc.
$14
SANOFI PASTEUR INC.
$14
AIMMUNE THERAPEUTICS, INC.
$14
Mylan Pharmaceuticals Inc.
$14
Mylan Institutional Inc.
$13
Teva Pharmaceuticals USA, Inc.
$13
AbbVie, Inc.
$11
Top 3 companies account for 45.9% of all-time payments
Associated products mentioned in payments ›
AFREZZA · AJOVY · ANORO · ANORO ELLIPTA · APRETUDE · Aimovig · Arikayce · BASAGLAR · BREZTRI · Baxdela · CABENUVA · CUTAQUIG · CYCLOSET · Cimduo · Cologuard Collection Kit · DALVANCE · DELSTRIGO · DIFICID · DOVATO · EGRIFTA · ELIQUIS · EMGALITY · EVENITY · Edarbi · FARXIGA · FLUBLOK QUADRIVALENT · FLUZONE HIGH-DOSE · Fetroja · GARDASIL 9 · Horizant · ISENTRESS · JARDIANCE · JULUCA · Kimyrsa · Livalo · MAVYRET · MOUNJARO · Mavyret · Mytesi · NOXAFIL · NUZYRA · Otezla · Ozempic · PAXLOVID · PIFELTRO · PNEUMOVAX 23 · PREVNAR 20 · PREZCOBIX · PREZISTA · Prolia · QULIPTA · RUCONEST · RUKOBIA · RYBELSUS · Rybelsus · SEROSTIM · SOLIQUA · SOLIQUA 100/33 · SPIRIVA RESPIMAT · SPRAVATO · STIOLTO RESPIMAT · SYMTUZA · Serostim · Symfi Lo · Symtuza · TOUJEO · TRELEGY ELLIPTA · TRIUMEQ · TROGARZO · TRULICITY · Tresiba · UBRELVY · VERQUVO · VIBATIV · VOQUEZNA · VOWST · Vibativ · Victoza · XERAVA · Xembify · ZEPBOUND · ZERBAXA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Infectious diseases in nearby ZIP areas
636
County median income
$87,137
Nearest hospital to ZIP centroid (approximate)
ST JOSEPH'S UNIVERSITY MEDICAL CENTER INC
2.2 mi
2.2 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Najjar is a mixed practice specialist, with above-average Medicare volume (top 6% in NJ), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Najjar experienced with injection, meropenem, 100 mg?
Based on Medicare claims data, Dr. Najjar performed 2,971 injection, meropenem, 100 mg services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Najjar receive payments from pharmaceutical companies?
Yes. Dr. Najjar received a total of $12,557 from 48 companies across 887 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Najjar's costs compare to other infectious diseases in Clifton?
Dr. Najjar's average Medicare payment per service is $25. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Najjar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Infectious Diseases in Clifton
Browse infectious diseases in Clifton ranked by procedure volume and transparency data.
Highest volume
Top Infectious Diseases in NJ
Infectious diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Infectious Diseases in NJ
Which NJ infectious diseases receive the most from drug and device companies.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
By company
Novo Nordisk Inc Payments to Doctors
See all physicians who received payments from Novo Nordisk Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology